ADD THIS DRUG TO MY LIST

Select the drug indication to add to your list

GAMMAPLEX 5%
Bleeding disorders
Primary immune deficiency
Compare To Related Drugs
View/Edit/Compare Drugs In My List

Only 4 drugs may be compared at once

Drug Name:

GAMMAPLEX 5% Rx

Generic Name and Formulations:
Immune globulin (human) 5g/100mL, 10g/200mL, 20g/400mL; liq for IV infusion; sucrose-, maltose-, preservative- and latex-free.

Company:
BPL Inc.

Therapeutic Use:

Indications for GAMMAPLEX 5%:

Chronic immune thrombocytopenic purpura (ITP).

Adult:

Individualize. 1g/kg (20mL/kg) given on 2 consecutive days by IV infusion at a rate of 0.5mg/kg/min for 15mins, if tolerated may increase at 15min intervals up to max 4mg/kg/min. Risk of thrombosis, volume overload, renal dysfunction or acute renal failure: give at the minimum practicable infusion rate. See full labeling.

Children:

Not recommended.

Contraindications:

Previous severe reaction to human immune globulin. Hereditary intolerance to fructose. Infants and neonates without established sucrose or fructose tolerance. IgA deficiency with antibodies against IgA.

Warnings/Precautions:

Advanced age, prolonged immobilization, hypercoagulable conditions, history of venous or arterial thrombosis, use of estrogens, indwelling central vascular catheters, hyperviscosity, cardiovascular risk factors: increased risk of thrombosis. Monitor for signs/symptoms of thrombosis and assess blood viscosity in patients at risk for hyperviscosity. Ensure adequate hydration. Pre-existing renal insufficiency, diabetes, >65yrs, overweight, hypovolemia, sepsis, paraproteinemia: increased risk of renal dysfunction or acute renal failure. Correct volume depletion prior to initiation. Assess renal function, BUN, serum creatinine, urine output before and during therapy; discontinue if renal function deteriorates. Discontinue if hypersensitivity reactions occur; have epinephrine available. Monitor for aseptic meningitis; consider a thorough neurological examination. Monitor for hemolysis and hemolytic anemia; consider measuring baseline hemoglobin or hematocrit and approx. 36–96hrs post-infusion in high risk patients. Monitor for pulmonary adverse reactions; perform test for anti-neutrophil antibodies if transfusion-related acute lung injury (TRALI) is suspected. Volume overload. Risk of transmission of infectious agents. Elderly. Pregnancy. Nursing mothers.

Interactions:

May interfere with immune response to live virus vaccines. Concomitant nephrotoxic drugs: increased risk of acute renal failure. May cause false (+) serological test results or (+) direct or indirect antiglobulin (Coombs’) test.

Pharmacological Class:

Immune globulin.

Adverse Reactions:

Headache, pyrexia, nasal congestion/edema, fatigue, nausea, hypertension, rash, hypotension, infusion site reaction, vomiting, myalgia, chills, tachycardia, chest pain/discomfort, pain, dizziness, malaise, dysuria, dry skin; thrombosis, aseptic meningitis syndrome (esp. with high doses or rapid infusion), hemolysis, hemolytic anemia, TRALI. Also ITP: pruritus, dehydration, arthralgia.

Generic Availability:

NO

How Supplied:

Single-use bottle—1

Indications for GAMMAPLEX 5%:

Primary humoral immunodeficiency (eg, common variable immunodeficiency, X-linked agammaglobulinemia, congenital agammaglobulinemia, Wiskott-Aldrich syndrome, severe combined immunodeficiencies).

Adults and Children:

<2yrs: not established. Individualize. ≥2yrs: 300–800mg/kg by IV infusion every 3–4 weeks at a rate of 0.5mg/kg/min for 15mins, if tolerated may increase at 15 min intervals up to max 4mg/kg/min. Risk of thrombosis, volume overload, renal dysfunction or acute renal failure: give at the minimum practicable infusion rate. See full labeling.

Contraindications:

Previous severe reaction to human immune globulin. Hereditary intolerance to fructose. Infants and neonates without established sucrose or fructose tolerance. IgA deficiency with antibodies against IgA.

Warnings/Precautions:

Advanced age, prolonged immobilization, hypercoagulable conditions, history of venous or arterial thrombosis, use of estrogens, indwelling central vascular catheters, hyperviscosity, cardiovascular risk factors: increased risk of thrombosis. Monitor for signs/symptoms of thrombosis and assess blood viscosity in patients at risk for hyperviscosity. Ensure adequate hydration. Pre-existing renal insufficiency, diabetes, >65yrs, overweight, hypovolemia, sepsis, paraproteinemia: increased risk of renal dysfunction or acute renal failure. Correct volume depletion prior to initiation. Assess renal function, BUN, serum creatinine, urine output before and during therapy; discontinue if renal function deteriorates. Discontinue if hypersensitivity reactions occur; have epinephrine available. Monitor for aseptic meningitis; consider a thorough neurological examination. Monitor for hemolysis and hemolytic anemia; consider measuring baseline hemoglobin or hematocrit and approx. 36–96hrs post-infusion in high risk patients. Monitor for pulmonary adverse reactions; perform test for anti-neutrophil antibodies if transfusion-related acute lung injury (TRALI) is suspected. Volume overload. Risk of transmission of infectious agents. Elderly. Pregnancy. Nursing mothers.

Interactions:

May interfere with immune response to live virus vaccines. Concomitant nephrotoxic drugs: increased risk of acute renal failure. May cause false (+) serological test results or (+) direct or indirect antiglobulin (Coombs’) test.

Pharmacological Class:

Immune globulin.

Adverse Reactions:

Headache, pyrexia, nasal congestion/edema, fatigue, nausea, hypertension, rash, hypotension, infusion site reaction, vomiting, myalgia, chills, tachycardia, chest pain/discomfort, pain, dizziness, malaise, dysuria, dry skin; thrombosis, aseptic meningitis syndrome (esp. with high doses or rapid infusion), hemolysis, hemolytic anemia, TRALI. Also ITP: pruritus, dehydration, arthralgia.

Generic Availability:

NO

How Supplied:

Single-use bottle—1

Sign Up for Free e-newsletters

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs